AZN shares post their worst session since 2020 on unconfirmed merger talk with BMY
Reports of merger discussions between AstraZeneca PLC (NYSE: AZN) and Bristol-Myers Squibb Company (NYSE: BMY) sent AZN shares down as much as 9% on Monday, the stock's steepest one-day drop since 2020. Neither company confirmed the talks. People familiar with the matter told Reuters the deal may never materialize, and the market's reaction suggests most AstraZeneca investors are counting on exactly that.
Key takeaways
- AstraZeneca (AZN) shares fell as much as 9% on Monday—their steepest one-day drop since 2020—on unconfirmed reports of merger talks with Bristol-Myers Squibb (BMY).
- Neither AstraZeneca nor Bristol-Myers confirmed the talks, and sources told Reuters the deal may never materialize.
- Bristol-Myers shares rose as much as 6% on the news, and a combined company would be worth close to $400 billion, the fourth-largest global drugmaker.
- AstraZeneca CEO Pascal Soriot said last week the company doesn't need M&A to hit its target of $80 billion in annual revenue by 2030, up from $58.7 billion last year.
- BMY faces patent expiration on its top products Eliquis and Opdivo, positioning it as the party that would benefit more from the deal.
Reports of merger discussions between AstraZeneca PLC (NYSE: AZN) and Bristol-Myers Squibb Company (NYSE: BMY) sent AZN shares down as much as 9% on Monday, the stock's steepest one-day drop since 2020. Neither company confirmed the talks. People familiar with the matter told Reuters the deal may never materialize, and the market's reaction suggests most AstraZeneca investors are counting on exactly that.
The split in the tape was hard to miss. Bristol-Myers shares climbed as much as 6% on the same news before pulling back. A combined entity would carry a market value of close to $400 billion, placing it fourth-largest among global drugmakers.
The numbers in focus
AstraZeneca targets $80 billion in annual revenue by 2030, up from $58.7 billion last year. CEO Pascal Soriot said last week the company doesn't "need M&A to deliver" on that goal. The firm already earns 42% of its sales in the U.S. and completed a direct U.S. stock listing this year. Jefferies analysts said they were "a bit perplexed" by the report given AstraZeneca's organic growth record under Soriot.
Shareholder pushback arrived quickly. Union Investment's Markus Manns said the deal "does not make strategic or financial sense." ATG Healthcare's Lukas Leu called it growth-dilutive in the near term. The drop landed weeks after a separate late-stage trial failure had already raised questions about management credibility, giving critics a second opening.
Why BMY looks like the side that needs the deal
Bristol-Myers Squibb's two largest products, blood thinner Eliquis and cancer drug Opdivo, both face patent expiration and generic competition in the coming years, with growth expected to decline starting next year. BMY shares are already up over 22% year to date as of July 31. A deal would pair the company with a partner carrying less patent-expiry pressure and a deeper pipeline, potentially producing the broadest oncology portfolio in the industry. BMO analyst Evan Seigerman noted that heavy overlap between Bristol's Opdivo and AstraZeneca's Imfinzi could reduce the odds of a successful merger on antitrust grounds alone.
On the institutional read, Insider Monkey's Q1 2026 hedge fund database shows AZN with 56 holders, up from 52 the prior quarter, with aggregate dollar value rising from about $4.21 billion to $5.50 billion. BMY counted 83 holders, up slightly from 82. Pfizer sits at the same 83; Merck stands at 98.
What to watch: no definitive agreement has been announced. The next confirmable step is a formal statement from either board or a regulatory filing. AZN's setup from here rests on whether Soriot's stated preference for organic growth holds or the Reuters sourcing proves out.
Related reading
Filed by the newsroom of MarketPR on August 14, 2026. Source: finance.yahoo.com. Indicative figures are not investment advice.